ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
By Elana Gotkine HealthDay Reporter

THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality, substance misuse, transport accidents, and criminality, according to a study published online Aug. 13 in The BMJ.
Le Zhang, M.P.H., from the Karolinska Institutet in Stockholm, and colleagues examined the effects of drug treatment for ADHD on suicidal behaviors, substance misuse, accidental injuries, transport accidents, and criminality in an emulation of target trials involving people aged 6 to 64 years with a new diagnosis of ADHD. First and recurrent events of five outcomes were examined over two years after ADHD diagnosis.
Of 148,581 individuals with ADHD, 56.7 percent started drug treatment for ADHD; methylphenidate was prescribed most commonly at initiation (88.4 percent). The researchers found that drug treatment for ADHD was associated with significantly reduced rates of the first occurrence of suicidal behaviors, substance misuse, transport accidents, and criminality (adjusted incidence rate ratios, 0.83, 0.85, 0.88, and 0.87, respectively), while the reduction in accidental injuries was not statistically significant. Individuals with previous events had more pronounced reduced rates, with incidence rate ratios varying from 0.79 to 0.97 for suicidal behaviors and accidental injuries, respectively. Drug treatment was significantly associated with reduced rates of all five outcomes for recurrent events (0.85, 0.75, 0.96, 0.84, and 0.75 for suicidal behaviors, substance misuse, accidental injuries, transport accidents, and criminality, respectively).
"These results provide evidence on the effects of ADHD drug treatment on important health related and social outcomes that should inform clinical practice and the debate on the drug treatment of ADHD," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-08-15 06:00
Read more

- FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
- Higher Intake of Total Potatoes Linked to Type 2 Diabetes Risk
- Johnson & Johnson Seeks First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
- Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
- Living Near Polluted Missouri Creek as a Child Tied to Later Cancer Risk
- Johnson & Johnson Receives U.S. FDA Priority Review for TAR-200 NDA in High-Risk Non-Muscle Invasive Bladder Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions